clinicaladvisor.com

Managing Tardive Dyskinesia–Associated Chorea-Ballism With Valbenazine

A case report indicates that valbenazine may be an effective therapy for chorea-ballism associated with tardive dyskinesia. Valbenazine has therapeutic potential to improve chorea-ballism associated ...
Healio

FDA approves new doses of Austedo XR for tardive dyskinesia, Huntington’s chorea

Please provide your email address to receive an email when new articles are posted on . The new once-daily tablet strength doses are 30 mg, 36 mg, 42 mg and 48 mg. Symptom improvement in tardive ...
Healio

FDA approves Ingrezza sprinkle capsules for tardive dyskinesia, Huntington’s chorea

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Ingrezza sprinkle capsules to treat adults with Huntington’s disease chorea or tardive ...
Monthly Prescribing Reference

Valbenazine Fails to Improve Chorea In Dyskinetic Cerebral Palsy Trial

The study did not meet its primary endpoint of chorea improvement or key secondary endpoints at the time of analysis. Topline data were announced from a phase 3 trial evaluating valbenazine in ...
Seeking Alpha

Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Capsules Data Demonstrating Early and Sustained Improvements in Chorea Associated With Huntington's Disease

SAN DIEGO, Aug. 28, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) (Nasdaq: NBIX) today announced new data on now FDA-approved INGREZZA ® (valbenazine) capsules for the treatment of adults ...
Seeking Alpha

Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of ...

SAN DIEGO, Sept. 30, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) (Nasdaq: NBIX) today announced interim results from the ongoing open-label KINECT ®-HD2 study of INGREZZA ® (valbenazine) ...
Monthly Prescribing Reference

FDA to Review New Formulation of Ingrezza for Tardive Dyskinesia, Huntington Disease Chorea

Credit: FDA. The new sprinkle formulation is intended to be opened for sprinkling on soft foods prior to administration. The Food and Drug Administration (FDA) has accepted for review the New Drug ...
BioWorld

Neurocrine’s Ingrezza gets expanded FDA nod in chorea associated with HD

The impact of a black box warning on Neurocrine Biosciences Inc.’s expanded U.S. label for Ingrezza (valbenazine) to treat chorea associated with Huntington’s disease (HD) appears up for debate, ...
Nasdaq

Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition

IMPACT-TD Registry, the largest study evaluating holistic effects of tardive dyskinesia (TD), highlights that there is a high burden of TD on quality of life regardless of a person’s underlying mental ...
Morningstar

Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR

SAN DIEGO, Jan. 15, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of the first head-to-head data comparing vesicular monoamine transporter 2 (VMAT2) ...
Business Insider

Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Capsules Data Demonstrating Early and Sustained Improvements in Chorea Associated With Huntington's Disease

Data Presented at the 2023 MDS International Congress of Parkinson's Disease and Movement Disorders ® SAN DIEGO, Aug. 28, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today ...